First Patient Treated in RenovoCath Clinical Trial

RenovoRx Inc.'s study of its U.S. Food and Drug Administration (FDA)-cleared drug delivery device, RenovoCath, has marked a major milestone with the first patient treatment at the University of Vermont Cancer Center.

RenovoRx also announced that Baptist Health Miami Cancer Institute and University of Pittsburgh Medical Center have joined the University of Vermont Cancer Center as participating clinical sites in the PanTheR registry study. Principal investigators at the first three PanTheR clinical sites include Dr. Ripal Gandhi, interventional radiologist at Baptist Health Miami Cancer Institute; Dr. Paula Novelli, interventional radiologist at University of Pittsburgh Medical Center; and Dr. Conor O'Neill, surgical oncologist at the University of Vermont Cancer Center. The study began at the University of Vermont Cancer Center with Dr. O'Neill's team; the additional two sites are expected to initiate patient procedures soon.

Read the full article on Medical Product Outsourcing